Showing results (261-270 of 364) with videos related to
Sort By:
Pageof 37
BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.Pediatric Dermatology|March 23, 2023
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 studyLawrence F Eichenfield, Linda Stein Gold, Leon H Kircik, et al.Journal of the American Academy of Dermatology|January 27, 2022
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adultsDawn M R Davis, Aaron M Drucker, Ali Alikhan, et al.Immunotherapy|February 27, 2025
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Eric Simpson, Robert Bissonnette, et al.American Journal of Clinical Dermatology|May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 StudiesLawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.Journal of the American Academy of Dermatology|June 17, 2017
Evidence-based recommendations for the management of acne fulminans and its variantsTanya Greywal, Andrea L Zaenglein, Hilary E Baldwin, et al.American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 20, 2021
Pharmacist intervention on prescribing errors: Use of a standardized approach in the inpatient settingAnn Cabri, Naira Barsegyan, Michael Postelnick, et al.BMC Research Notes|June 28, 2013
"Affect of anaerobiosis on the antibiotic susceptibility of H. influenzae"Hannah Kendall Smith, Kevin Lee Nelson, Edison S Calaunan, et al.Science Advances|January 6, 2023
Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteriaJordan Zeldin, Prem Prashant Chaudhary, Jacquelyn Spathies, et al.Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.Pageof 37